Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ATYR stock hub

aTyr Pharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ATYRis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

92.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ATYR

In the news

Latest news · ATYR

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-108.1

P25 -105.6P50 -46.5P75 -3.1

ROIC-59.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ATYR market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001339970
Company name	aTyr Pharma, Inc.
Country	United States
Country code	US
Cusip	002120202
Employees	60
Employees Change	1%
Employees Change Percent	1.69
Enterprise value	$26.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-05-07
Isin	US0021202025
Last refreshed	2026-05-10
Market cap	$92.8M
Market cap category	Micro-Cap
Price	$0.95
Price currency	USD
Rev Per Employee	3,166.67x
Sector	Healthcare
Sic	2836
Symbol	ATYR
Website	https://atyrpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-79.88%
EV/Sales	137.54x
FCF yield	-66.89%
P/B ratio	1.37x
P/S ratio	488.35x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-60M
Net Income	$-74.1M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-39,012.11%
Profit Per Employee	$-1.2M
ROA	-51.12
Roa5y	-35.38
ROCE	-99.71
ROE	-108.1
Roe5y	-69.72
ROIC	-59.74

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-31.79%
Cagr1y	-70.08%
Cagr3y	-23.93%
Cagr5y	-24.36%
EPS Growth Quarters	1
EPS Growth Years	4
Revenue Growth	-19.15x
Revenue Growth Years	0x
Revenue Growth3 Y	-73.65x
Revenue Growth5 Y	-55.14x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0
Assets	$93M
Cash	$78.7M
Current Assets	$80.2M
Current Liabilities	$15.1M
Debt	$12M
Debt Equity	$0.18
Equity	$67.3M
Liabilities	$25.7M
Long Term Assets	$12.8M
Long Term Liabilities	$10.6M
Net Cash	$66.7M
Net Cash By Market Cap	$71.84
Net Cash Growth	13.28%
Net Debt Equity	$-0.99
Tangible Book Value	$67.5M
Tangible Book Value Per Share	$0.69
WACC	7

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.3
Net Working Capital	$-12.1M
Quick ratio	5.25
Working Capital	$65.1M
Working Capital Turnover	$0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-25.21%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-97.82%
1Y total return	-70.05%
200-day SMA	1.64
3Y total return	-55.99%
50-day SMA	0.85
50-day SMA vs 200-day SMA	50under200
5Y total return	-75.23%
All Time High	396.1
All Time High Change	-99.76%
All Time High Date	2015-06-04
All Time Low	0.64
All Time Low Change	47.86%
All Time Low Date	2025-11-21
ATR	0.07
Beta	0.66
Beta1y	0.74
Beta2y	1.08
Ch YTD	20.84
High	0.96
High52	7.29
High52 Date	2025-07-28
High52ch	-87.02%
Low	0.9
Low52	0.64
Low52 Date	2025-11-21
Low52ch	47.86%
Ma50ch	11.78%
Premarket Change Percent	2.63
Premarket Price	$0.95
Premarket Volume	24,492
Price vs 200-day SMA	-42.26%
RSI	59.13
RSI Monthly	39.62
RSI Weekly	43.05
Sharpe ratio	0.08x
Sortino ratio	0.14
Total Return	-25.21%
Tr YTD	20.84
Tr1m	19.02%
Tr1w	13.53%
Tr3m	5.26%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	3
Analyst Price Target Top	$6.33
Analyst Ratings	Hold
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.15
Earnings Revenue Estimate	20,000x
Operating Income	$-77.6M
Operating margin	-40,856.3
Price target	$3.67
Price Target Change	$288
Price Target Change Top	$569

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	95,611,137%
Float Percent	97.51%
Net Borrowing	-539,000
Shares Insiders	2.49%
Shares Institutions	54.25%
Shares Out	98,051,212
Shares Qo Q	0.88%
Shares Yo Y	25.21%
Short Float	20.8%
Short Ratio	20.24
Short Shares	20.28

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-67.1M
Average Volume	1,032,795.8x
Bv Per Share	0.69
CAPEX	$-77,000
Ch10y	-97.82
Ch1m	19.02
Ch1w	13.53
Ch1y	-70.05
Ch3m	5.26
Ch3y	-55.99
Ch5y	-75.23
Ch6m	15.84
Change	2.66%
Change From Open	0.67
Close	0.92
Days Gap	1.97
Depreciation Amortization	664,000
Dollar Volume	856,538.7
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-77.6M
EBITDA	$-77M
EPS	$-0.8
F Score	2
FCF	$-62.1M
FCF EV Yield	-237.5x
FCF Per Share	$-0.63
Financing CF	66,011,000
Fiscal Year End	December
Founded	2,005
Investing CF	-5,053,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-05
Last Report Date	2025-12-31
Last Split Date	2019-07-01
Last Split Type	Reverse
Last10k Filing Date	2026-03-05
Ma150	0.83
Ma150ch	13.4%
Ma20	0.84
Ma20ch	12.25%
Net CF	-1,028,000
Next Earnings Date	2026-05-22
Open	0.94
Optionable	Yes
Position In Range	76.62
Post Close	0.95
Postmarket Change Percent	-2.46
Postmarket Price	$0.92
Ppne	10,383,000
Pre Close	0.92
Price Date	2026-05-08
Ptbv Ratio	1.38
Relative Volume	0.88x
Revenue	190,000x
SBC By Revenue	2,630x
Share Based Comp	4,997,000
Tr6m	15.84%
Us State	California
Volume	905,145
Z Score	-4.26

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ATYR pay a dividend?

Capital-return profile for this ticker.

Performance

ATYR stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ATYR?

Insider, institutional, and short-interest positioning.

Institutional ownership

+54.3%

Float: +97.5% of shares outstanding

Insider ownership

+2.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ATYR momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.1

Neutral momentum band

Price vs 200-day MA

-42.3%

50/200-day relationship not available

Beta (5Y)

0.66

Less volatile than the market

Sharpe ratio

0.08

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ATYR

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ATYR stock rating?

aTyr Pharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ATYR analysis?

The full report lives at /stocks/ATYR/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ATYR?

The latest report frames ATYR around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ATYR page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.